Refractory Anemia With Excess Blasts in Transformation

DBCOND0028567Hemic and Lymphatic Diseases Neoplasms

Refractory Anemia With Excess Blasts in Transformation is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as: Refractory Anemia With Excess of Blasts in Transformation · MDS-refractory anemia with excess of blasts in transformation (RAEB-T)
Classified under: Hemic and Lymphatic Diseases
Neoplasms
Indicated drugs: Azacitidine
Decitabine

Resolves to

Vocabularies

ICD-10C92.0SNOMED CT110000005MedDRA10038271UMLSC0280028

What you can answer from here — as of November 01, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

22Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Refractory Anemia With Excess Blasts in Transformation share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account